Results 251 to 260 of about 421,443 (284)

Legionnaires' Disease Presenting With Erythema Multiforme in an Immunocompetent Patient. [PDF]

Cureus
Wayzani A, Dib J, Bertrac J.
europepmc   +1 more source

Nature's cryptographic codebreaker<i>: in silico</i> decoding of apigenin's triple defense against SARS-CoV-2. [PDF]

Front Microbiol
Huang J, Fang Y, Guan H, Hu S.
europepmc   +1 more source

Nodding Syndrome: The Need to Strengthen Epilepsy Care in Onchocerciasis-Endemic Areas and to Investigate the Pathogenesis of Onchocerciasis-Associated Epilepsy. [PDF]

Am J Trop Med Hyg
Hadermann A, Colebunders R.
europepmc   +1 more source

Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model. [PDF]

PLoS One
Shimazu Y, Isoda N, Hiono T, Hew YL, Kobayashi D, Shibazaki M, Nguyen BL, Morita T, Obara RD, Miki M, Osaki H, Shishido T, Ikenaka Y, Sakoda Y.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Characterization of Virus Particles and Submicron-Sized Particulate Impurities in Recombinant Adeno-Associated Virus Drug Product

Journal of Pharmaceutical Sciences, 2023
Characterization of particulate impurities such as aggregates is necessary to develop safe and efficacious adeno-associated virus (AAV) drug products. Although aggregation of AAVs can reduce the bioavailability of the virus, only a limited number of studies focus on the analysis of aggregates.
Cornelia Hiemenz, Anabel Pacios-Michelena, Constanze Helbig, Valerija Vezočnik, Michael Strebl, Felix Nikels, Andrea Hawe, Patrick Garidel, Tim Menzen   +8 more
openaire   +2 more sources

Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)

Clinical Endocrinology, 2021
AbstractBackground and ObjectiveHypoglycemia induced by direct‐acting antiviral agents (DAAs) for chronic hepatitis C virus (HCV) infection is a rare but potentially life‐threatening adverse reaction, which led to warnings by competent authorities. We therefore aimed to examine the hypoglycemic safety signal for DAAs.MethodsReports to the US Food and ...
Yu, Zhou, Wenhuo, Xie, Chenhua, Zheng, Libin, Liu, Zhou, Chen, Xiaolu, Wang   +5 more
openaire   +2 more sources

Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

Drug Resistance Updates, 2018
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence ...
Sorbo M. C., Cento V., Di Maio V. C., Howe A. Y. M., Garcia F., Perno C. F., Ceccherini-Silberstein F.   +6 more
openaire   +3 more sources

Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs

Hepatology Research, 2019
AimsDevelopment of direct‐acting antivirals (DAAs) has made antihepatitis C virus (HCV) treatment highly safe and effective. However, the emergence of resistant‐associated variants (RAVs) after failure of DAA therapy affects retreatment outcomes. In particular, genotype 1 HCV with P32 deletion has been reported to be highly resistant to all approved ...
Goki Suda, Megumi Kimura, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto   +14 more
openaire   +2 more sources